FAPI PET Prostate Cancer
Lay Title A prospective exploratory imaging study of 68Ga-FAPI-46 PET/CT Scan in Patients with Prostate Cancer
Technical Title: PET biodistribution study of 68Ga-FAPI-46 in patients with prostate cancer: an exploratory biodistribution study with histopathology validation.
Disease Type: Prostate Cancer
Basic information: The purpose of this research study is to determine where and to which the FAPI tracer (68Ga-FAPI-46) accumulates in normal and prostate cancer tissue. This can be determined by what is seen on PET/CT images represents the tumor tissue that is being excised from the body via surgery or biopsy.
Research Procedures: This trial will enroll 30 patients with prostate cancer that underwent a 68Ga-PSMA-11 PET/CT 3 months prior to 68Ga-FAPI-46 PET/CT scan. 68Ga-FAPI-46 will be used as the FAP-targeted PET radiopharmaceutical. The administered dosage is 111-259 MBq iv (3-7 mCi i.v)
The PET/CT scan during the visit in the nuclear medicine clinic will be free of charge.
More detailed information on clinicaltrials.gov
For More Detailed Information, Contact: